Suggestions
Sonali Bloom
CEO, 20/20 Onsite: Expanding access to care by bringing primary eye care directly to patients and transforming clinical trials.
Sonali Bloom is the Chief Executive Officer of 20/20 Onsite, a company focused on revolutionizing vision care. She has held this position since April 2022, previously serving as Vice President of Product & Experience from October 2019 to April 2022. During her tenure, she has overseen various departments including Product Management, Technology, Sales, Marketing, and Client Success, and has been instrumental in launching new initiatives such as telehealth services during the COVID-19 pandemic.1
Education and Early Career
Sonali holds an MBA with Distinction from Harvard Business School (2015-2017) and a Bachelor of Science in Physics from Yale University. Prior to her role at 20/20 Onsite, she worked in several leadership positions, including Senior Director of Operations & Client Experience at the same company and Senior Director of Product Strategy at Decision Resources Group.1
Professional Impact
Under her leadership, 20/20 Onsite has expanded its services to include pro bono programs in partnership with local educational institutions, emphasizing her commitment to community health initiatives. Sonali's strategic vision aims to enhance access to eye care by integrating innovative solutions into clinical practices.1
Highlights
The rise of diabetes and obesity treatments will have tremendous benefits for patients - and for their families, communities, and society.
We've got our eyes on the recent studies that have revealed a link between these treatments and sight-threatening disorders. This underscores the critical need for ocular assessments in obesity and diabetes clinical trials.
At 20/20 Onsite, we provide eye assessments at the point of need for the patient, ensuring that all ocular endpoints are meticulously evaluated by certified professionals using state-of-the-art equipment. Our mobile clinics bring these services directly to clinical trial sites, enhancing patient care and trial outcomes.
If you’re involved in diabetes or obesity trials, don’t let ocular endpoints be a blind spot. Our expertise can help mitigate risks and ensure the success of your study.
https://lnkd.in/efEtnpnk
#ClinicalTrials #ObesityResearch #DiabetesResearch #EyeCare #PharmaInnovation #PatientSafety
Proud sister here, shamelessly promoting my brother Sahil Bloom's book, which launched today! Sahil, I am truly so proud of and inspired by the curiosity, creativity, and hard work that you invest in everything that you do.
